title: DTIC xenogenized lines obtained from an L1210 clone: clonal analysis of cytotoxic T lymphocyte reactivity.
abstract: Antineoplastic compounds can induce on tumour cells new antigens that undetectable on parental cells and which are transmissible as a genetic character. In this study mouse leukaemia L1210 was cloned in vitro by limiting dilution and one cloned line was recloned in vivo. Four subcloned tumour cell lines (A,D,R,S) were xenogenized in vivo by DTIC treatment (A/DTIC, D/DTIC, R/DTIC, S/DTIC) following a schedule previously described. Up to 10(7) cells of these xenogenized subclones, injected i.p., were rejected by syngeneic hosts, although they grew in immunosuppressed hosts. The DTIC treated subclones were lysed by in vivo-primed, in vitro-restimulated (with the relevant subclone) lymphocytes. The cytotoxic lymphocyte activity was not strictly specific since parental, DTIC-untreated cells were also lysed, although less efficiently. CTL directed against the D/DTIC subclone were cloned by limiting dilution. Ninety-four CTL clones were assayed against L1210 subcloned cells, DTIC-treated and untreated, and against different murine tumours (syngeneic or allogenic). Three specific antigens could be identified in the 51Cr release assay. The DTIC subclones expressed one antigen that was specifically recognized by a set of CTL clones. A number of CTL clones were able to lyse the L1210 subcloned cell exclusively, targetting a tumour-associated antigen that did not appear to be modified in the DTIC-treated subclones. A third antigen was demonstrated in the parental and DTIC treated D subclone. On the basis of these results it was postulated that there was at least one common DTIC-inducible antigen specific and reproducible within an identical cell population. Moreover, DTIC treatment did not modify histocompatibility antigens or TAA pre-existing in L1210 cells. The findings discussed here provide new information about permanent xenogenization of tumour cells, which might be exploited for experimental chemo-immunotherapy of cancer.
authors: Department of Pharmacology, School of Medicine, Milan.
authors: O
authors: O
authors: Marelli
authors: P
authors: P
authors: Franco
authors: G
authors: G
authors: Canti
authors: L
authors: L
authors: Ricci
authors: N
authors: N
authors: Prandoni
authors: A
authors: A
authors: Nicolin
authors: H
authors: H
authors: Festenstein
mesh_terms: D000818:Animals; D000951:Antigens, Neoplasm / Q000276:immunology*; D002470:Cell Survival; D002999:Clone Cells; D003606:Dacarbazine / Q000494:pharmacology; D000939:Epitopes / Q000032:analysis; D005260:Female; D005802:Genes, MHC Class II; D007376:Interleukin-2 / Q000494:pharmacology; D007939:Leukemia L1210 / Q000276:immunology*; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*; D014407:Tumor Cells, Cultured / Q000187:drug effects / Q000276:immunology
chemical_list: D000951:Antigens, Neoplasm; D000939:Epitopes; D007376:Interleukin-2; D003606:Dacarbazine